TROP2 ADCs: The race to capture the next oncology opportunity
Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs. The post TROP2 ADCs: The race to capture the next oncology op...
Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs. The post TROP2 ADCs: The race to capture the next oncology op...
SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a hig...
Sacituzumab govitecan has become one of the most consequential weapons in modern oncology, a so-called antibody–drug conjugate that delivers a potent chemotherapy payload directly...
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed acr...
The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Ha...
Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer as Hansoh Pharma and Medilink bring momentum with positive results. The post B7-H3 ADCs: A new contender in small...
Our guest today is Robert Andrews, Partner and Patent Attorney at Mewburn Ellis. Robert has spent more than 20 years advising ADC companies on patent strategy. The post The ADC pat...
A 63-year-old patient with HER2-positive metastatic gastroesophageal junction adenocarcinoma achieved 23 months of progression-free survival on second-line trastuzumab deruxtecan f...
Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ded...
AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical compan...
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate sele...
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.